Small-molecule drugs arise as a prospective area to treat different types of cancer. A promising target is the NSD protein family. These proteins have been related to cancers like myeloid leukemia, multiple myeloma, prostate, lung, and breast cancer. However, their treatment is limited to chemotherapy, radiotherapy, and surgical operation that could affect the patient's life quality. In 2020, Huang and collaborators developed a novel kind of inhibitor for NSD1 protein, BT5. This inhibitor covalently binds to the SET domain of the NSD family proteins. However, there is a high affinity for NSD1 than their counterparts. These proteins share a similar structure, but their dynamics could explain the affinity difference. In this project, we compare the NSD family protein dynamics by measuring NMR relaxation experiments. We identify a higher percentage binding for NSD1 and NSD3 to BT5 than NSD2. We also determine the perturbed chemical shifts under the presence of BT5 in NSD1, where the most affected regions are the SET and post-SET domain (auto-inhibitory loop) and the beginning region of the AWS domain. By comparing different NMR relaxation measurements, we identify that the three proteins share high dynamics in the auto-inhibitory loop region, especially in NSD1, and in the AWS domain for NSD1 and NSD3. These motions corresponds to the obtained results by adding BT5 in NSD1, which could indicated a relationship between the AWS dynamics and the auto-inhibitory loop, and the protein affinity.
|Date of Award||Jul 2022|
|Original language||English (US)|
- Biological, Environmental Sciences and Engineering
|Supervisor||Lukasz Jaremko (Supervisor)|